Taxane-Based Regimens as Adjuvant Treatment for Breast Cancer: a Retrospective Study in Egyptian Cancer Patients

Azim, Hamdy A.; Abdal-Kader, Yasser Salah El Din; Mousa, Mohamed Mahmoud; Abdel-Malek, Raafat; Abdalmassih, Michael; Ibrahim, Noha

doi:10.7314/apjcp.2015.16.1.65

Cited by 4 publications

(12 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Three studies 30 , 32 , 37 presented data extracted from population-based cancer registries, while other three studies 22 , 28 , 42 were based on hospital-based cancer registries. Furthermore, 16 studies 16 , 17 , 24 - 26 , 31 , 33 - 36 , 38 - 41 , 43 , 44 had collected data retrospectively and three studies 23 , 27 , 29 were cross-sectional studies. The data represent BC cases presented during approximately 2 decades, from 1997 till 2015.…”

Section: Resultsmentioning

confidence: 99%

“…The data represent BC cases presented during approximately 2 decades, from 1997 till 2015. Eight studies 16 , 17 , 22 , 24 , 33 , 36 , 41 , 43 represented the capital (Cairo), while 11 15 , 23 , 27 , 30 - 32 , 35 , 37 - 39 , 42 and six studies 25 , 26 , 28 , 34 , 40 , 44 represented North and South Egypt, respectively; however, one study 29 presented patients with BC in the capital and North Egypt simultaneously. It is worth noting that different editions of the AJCC staging manual (4 th -7 th ) were used by most of the studies.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Clinicopathologic Features of Breast Cancer in Egypt—Contemporary Profile and Future Needs: A Systematic Review and Meta-Analysis

Azim

Elghazawy

Ghazy

et al. 2023

JCO Global Oncology

View full text Add to dashboard Cite

PURPOSE Breast cancer (BC) is the most common cancer among Egyptian females. No current national cancer database is available in Egypt to provide reliable data on the specific clinicopathologic features of BC in this population. Herein, we investigated the clinical profile of BC among Egyptian women. METHODS A systematic review of studies on BC published from inception until December 2021 was performed. We explored pooled estimated proportions of different stages of BC at presentation in Egypt and other clinicopathologic features including age, menopausal status, tumor (T) and lymph node (N) stages, and biological subtypes. Data analysis was performed using meta package (R). RESULTS Twenty-six studies were eligible for our systematic review and meta-analysis, including 31,172 BC cases. In 12 studies, including 15,067 patients with BC, the estimated mean age was 50.46 years (95% CI, 48.7 to 52.1; I2, 99%), with a pooled proportion of premenopausal/perimenopausal women of 57% (95% CI, 50 to 63; I2, 98%). Among 9,738 patients with BC, pooled proportions of stage I, II, III, and IV were 6% (95% CI, 4 to 8; I2, 90%), 37% (95% CI, 31 to 43; I2, 93%), 45% (95% CI, 42 to 49; I2, 78%), and 11% (95% CI, 9 to 15; I2, 87%), respectively. The pooled proportions of patients with T3 and T4 tumors were 21% (95% CI, 14 to 31; I2, 99%) and 8% (95% CI, 5 to 12; I2, 96%), respectively, while those with positive lymph nodes were 70% (95% CI, 59 to 79; I2, 99%). CONCLUSION Dominance of advanced stage and young age at diagnosis represented the two main features of BC among Egyptian women. Our data may serve to guide the policymakers in Egypt as well as other countries with lower resources to prioritize the diagnostic and therapeutic needs in this context.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Clinicopathologic Features of Breast Cancer in Egypt—Contemporary Profile and Future Needs: A Systematic Review and Meta-Analysis

Azim

Elghazawy

Ghazy

et al. 2023

JCO Global Oncology

View full text Add to dashboard Cite

show abstract

“…Breast cancer in Africa is characterized by disease in younger women with aggressive disease and poor hormone receptor staining which require the use of second and third generation drugs including Taxane-based chemotherapy [ 55 – 58 ]. These new drugs are considerably expensive with limited access in very few Sub-Saharan African health institutions [ 59 – 61 ].…”

Section: Systemic Therapiesmentioning

confidence: 99%

An update on the management of breast cancer in Africa

Vanderpuye

Grover

Hammad

et al. 2017

Infect Agents Cancer

120

124

View full text Add to dashboard Cite

BackgroundThere is limited information about the challenges of cancer management and attempts at improving outcomes in Africa. Even though South and North Africa are better resourceds to tackle the burden of breast cancer, similar poor prognostic factors are common to all countries. The five-year overall Survival rate for breast cancer patients does not exceed 60% for any low and middle-income country (LMIC) in Africa. In spite of the gains achieved over the past decade, certain characteristics remain the same such as limited availability of breast conservation therapies, inadequate access to drugs, few oncology specialists and adherence to harmful socio-cultural practices. This review on managing breast cancer in Africa is authored by African oncologists who practice or collaborate in Africa and with hands-on experience with the realities.MethodsA search was performed via electronic databases from 1999 to 2016. (PubMed/Medline, African Journals Online) for all literature in English or translated into English, covering the terms “breast cancer in Africa and developing countries”. One hundred ninety were deemed appropriate.ResultsBreast tumors are diagnosed at earlier ages and later stages than in highincome countries. There is a higher prevalence of triple-negative cancers. The limitations of poor nursing care and surgery, inadequate access to radiotherapy, poor availability of basic and modern systemic therapies translate into lower survival rate. Positive strides in breast cancer management in Africa include increased adaptation of treatment guidelines, improved pathology services including immuno-histochemistry, expansion and upgrading of radiotherapy equipment across the continent in addition to more research opportunities.ConclusionThis review is an update of the management of breast cancer in Africa, taking a look at the epidemiology, pathology, management resources, outcomes, research and limitations in Africa from the perspective of oncologists with local experience.

show abstract

“…Patients did not benefit from trastuzumab when indicated, and their DFS was limited to 59.7 months. Tumor size and lymph node status were the only independent variables affecting DFS, but our results showed that DFS was independent of all the studied variables and that completion of the planned chemotherapy cycles is the only determining factor of OS [4].…”

Section: Discussionmentioning

confidence: 50%

“…The only available data is limited to a retrospective analysis of 133 patients with early-stage breast cancer [4]. Patients did not benefit from trastuzumab when indicated, and their DFS was limited to 59.7 months.…”

Section: Discussionmentioning

confidence: 99%

Toxicities Associated with Docetaxel-Based Regimens in the Adjuvant Treatment of Early-Stage Breast Cancer: A Multicenter Prospective Real-Life Experience

et al. 2018

View full text Add to dashboard Cite

Background: The present study reports on the efficacy and safety of adjuvant docetaxel in real-life patients with early-stage breast cancer. Methods: This is a prospective, multicenter, post-marketing study that evaluates the efficacy and safety of docetaxel-based regimens in patients with early breast cancer treated between 2007 and 2012. Results: A total of 698 female breast cancer patients receiving adjuvant docetaxel-based regimens were included in this study. Docetaxel monotherapy was administered in 4.2%, whilst most patients received polychemotherapy. Non-hematological adverse events included skin reactions in 32.7% of the subjects. Multiple adverse events were reported and most commonly included asthenia (66.5%), alopecia (43.4%), and diarrhea (24.2%). It is noteworthy that no fatal toxicities occurred. Several hematological adverse events were reported during treatment, with anemia being the most common. Conclusion: The results of this real-life experience, characterized by a relatively large sample size and long follow-up, confirm that docetaxel is effective and well tolerated in early-stage breast cancer patients.

show abstract

Taxane-Based Regimens as Adjuvant Treatment for Breast Cancer: a Retrospective Study in Egyptian Cancer Patients

Cited by 4 publications

References 19 publications

Clinicopathologic Features of Breast Cancer in Egypt—Contemporary Profile and Future Needs: A Systematic Review and Meta-Analysis

Clinicopathologic Features of Breast Cancer in Egypt—Contemporary Profile and Future Needs: A Systematic Review and Meta-Analysis

An update on the management of breast cancer in Africa

Toxicities Associated with Docetaxel-Based Regimens in the Adjuvant Treatment of Early-Stage Breast Cancer: A Multicenter Prospective Real-Life Experience

Contact Info

Product

Resources

About